EBS: Emergent BioSolutions Inc. Stock

by  •  • Comments Off on EBS: Emergent BioSolutions Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 102.16
Enterprise Value ($M) 850.66
Book Value ($M) 649.30
Book Value / Share 12.39
Price / Book 0.16
NCAV ($M) -494.40
NCAV / Share -9.44
Price / NCAV -0.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.63

Liquidity (mrq)
Quick Ratio 0.54
Current Ratio 1.04

Balance Sheet (mrq) ($M)
Current Assets 679.50
Assets 1,823.20
Liabilities 1,173.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,049.30
Operating Income -178.70
Net Income -760.50
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -206.30
Cash from Investing 212.30
Cash from Financing -535.70

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 5.73 12.40
02-09 13G Charles Schwab Investment Management Inc 5.54
01-23 13G/A State Street Corp 2.05 -6.10
01-19 13G/A BlackRock Inc. 18.10 0.18
01-18 13G/A Millennium Management Llc 4.00 -22.71

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-12-11 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT
2023-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 181,759 755,772 24.05
2024-04-25 189,198 1,093,229 17.31
2024-04-24 201,066 799,932 25.14
2024-04-23 206,843 860,992 24.02
2024-04-22 415,611 1,393,297 29.83

(click for more detail)

Similar Companies
BHVN – Biohaven Ltd. BMY – Bristol-Myers Squibb Company
CTLT – Catalent, Inc. ELAN – Elanco Animal Health Incorporated
HYAC – Haymaker Acquisition Corp. 4


Financial data and stock pages provided by
Fintel.io